Schering-Plough Corporation 1994 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1994, for Schering-Plough Corporation, a holding company incorporated in New Jersey. The Company operates globally in the discovery, development, manufacturing, and marketing of pharmaceutical and health care products. As of December 31, 1994, the Company employed approximately 21,200 people, with 11,200 located outside the United States. Common shares outstanding as of January 31, 1995, were 186,057,622.
Key Financial Metrics
Consolidated sales for 1994 totaled $4,657 million, an increase from $4,341 million in 1993. Research and development expenditures were $620.0 million, representing approximately 13% of consolidated sales. The filing incorporates detailed financial statements by reference; specific values for net profit, operating margins, cash flow, debt, and liquidity are not explicitly stated in the provided text but are contained in the referenced 1994 Annual Report to Shareholders.
Material Changes and Segment Performance
Sales by major product groups for 1994 (in millions) showed the following trends compared to 1993:
- Respiratory: Increased to $1,465 million (from $1,185 million).
- Anti-infective and Anticancer: Decreased to $939 million (from $1,032 million).
- Dermatologicals: Increased to $488 million (from $443 million).
- Cardiovasculars: Increased to $333 million (from $316 million).
- OTC: Decreased to $264 million (from $312 million).
- Foot Care: Increased to $248 million (from $240 million).
- Animal Health: Increased to $167 million (from $154 million).
- Sun Care: Decreased to $129 million (from $131 million).
- Vision Care: Increased to $120 million (from $112 million).
Vision Care Strategy: The Company invested over $150 million to launch the FRESHLOOK disposable contact lens in 1994 to compete in the fastest-growing segment of the market. Management is currently reviewing options for the vision care business, including strategic alliances, licensing, or divestiture, with a decision expected in 1995.
Tax Impacts: Operations in Puerto Rico were partially impacted in 1994 by the Omnibus Budget Reconciliation Act of 1993, which phased down tax exemptions. New Puerto Rico tax laws also introduced a potential tollgate tax of 5% to 10% on remitted funds.
Outlook, Risks, and Contingencies
Legal Proceedings:
- Estrogen Litigation: The Company is a defendant in over 95 lawsuits involving more than 450 plaintiffs regarding synthetic estrogens, with total claims exceeding $2 billion. Management believes material liability in excess of accrued amounts is remote.
- THEO-DUR Judgment: A $63.6 million judgment (including $57.5 million in punitive damages) was entered against the Company in 1994. The Company is appealing and believes it has insurance coverage for amounts exceeding a $3 million retention, though carriers have reserved rights regarding punitive damages.
- Antitrust Actions: The Company is a defendant in more than 100 antitrust actions alleging price-fixing. Management believes these actions are without merit.
- Environmental: The Company is named as a potentially responsible party (PRP) in various Superfund proceedings. Management believes material liability in excess of accrued amounts is remote.
Regulatory and Competitive Risks:
- Patent Expirations: Generic competition is expected for PROVENTIL (asthma) following FDA bioequivalence standards issued in January 1994, which will negatively affect sales and profitability.
- Government Regulation: The Company faces cost containment programs and price controls in international markets and competitive pricing pressures from managed care groups in the U.S.
Investor Verification Checklist
- Verify the specific net income, operating margin, and cash flow figures in the referenced 1994 Annual Report to Shareholders, as they are not detailed in this text.
- Monitor the outcome of the $63.6 million THEO-DUR appeal and the status of insurance coverage for punitive damages.
- Track the strategic decision regarding the Vision Care business (divestiture vs. continuation) expected in 1995.
- Assess the impact of generic competition on PROVENTIL sales in 1995.
- Review the "Business Segment Data" in the Annual Report for detailed profitability by segment.